Frontiers in endocrinology · 2026
18F-FDOPA PET/CT for neuroendocrine tumors in multiple endocrine neoplasia type 1.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tepede Aisha A, Lee Maya, Welch James, Mandl Adel, Cochran Craig, Hamimi Ahmed, Weinstein Lee S, Simonds William F, Gharib Ahmed M, Millo Corina, Sadowski Samira M, Blau Jenny E, Jha Smita
Аннотация
OBJECTIVE: The aim of this study was to evaluate the efficacy of 6-18F-fluoro-L-3,4-dihydroxyphenylalanine (18F-FDOPA) positron emission tomography/computed tomography (PET/CT) in the identification of primary and metastatic NETs in patients with multiple endocrine neoplasia type 1 (MEN1).
DESIGN: This prospective MEN1 cohort study evaluated 16 genetically confirmed patients with MEN1. Inpatient subjects were imaged using CT, magnetic resonance imaging (MRI), 68Ga-DOTATATE PET/CT, and 18F-FDOPA PET/CT. A composite reference test combining up to 3 years of historical imaging and a multidisciplinary evaluation was used against the index test. Lesion-, patient-, and site-based analyses were performed.
SETTING: The NIH Clinical Center was the setting for this study.
PATIENTS: Patients with germline MEN1 variants confirmed to have MEN1 were included in the study.
RESULTS: A total of 134 lesions were identified after review of CT, MRI, and 68Ga-DOTATATE PET/CT. 18F-FDOPA PET/CT detected 17% (23/134, 95% CI: 8.2-27.1). Of the total study participants, 50% (8/16) of the patients had 18F-FDOPA PET/CT uptake in primary and metastatic sites with overlapping 68Ga-DOTATATE PET/CT uptake and localization on CT and MRI. Region-based analysis showed that 18F-FDOPA PET/CT had the highest avidity for lung (4/12, 33%) and pancreatic (8/38, 21%) NETs.
CONCLUSION: 18F-FDOPA PET/CT has low efficacy overall in detecting MEN1-related NETs.
CLINICAL TRIAL REGISTRATION: https://clinicalstudies.info.nih.gov/protocoldetails.aspx?id=000344-DK&&query=, identifier NCT04969926.
DESIGN: This prospective MEN1 cohort study evaluated 16 genetically confirmed patients with MEN1. Inpatient subjects were imaged using CT, magnetic resonance imaging (MRI), 68Ga-DOTATATE PET/CT, and 18F-FDOPA PET/CT. A composite reference test combining up to 3 years of historical imaging and a multidisciplinary evaluation was used against the index test. Lesion-, patient-, and site-based analyses were performed.
SETTING: The NIH Clinical Center was the setting for this study.
PATIENTS: Patients with germline MEN1 variants confirmed to have MEN1 were included in the study.
RESULTS: A total of 134 lesions were identified after review of CT, MRI, and 68Ga-DOTATATE PET/CT. 18F-FDOPA PET/CT detected 17% (23/134, 95% CI: 8.2-27.1). Of the total study participants, 50% (8/16) of the patients had 18F-FDOPA PET/CT uptake in primary and metastatic sites with overlapping 68Ga-DOTATATE PET/CT uptake and localization on CT and MRI. Region-based analysis showed that 18F-FDOPA PET/CT had the highest avidity for lung (4/12, 33%) and pancreatic (8/38, 21%) NETs.
CONCLUSION: 18F-FDOPA PET/CT has low efficacy overall in detecting MEN1-related NETs.
CLINICAL TRIAL REGISTRATION: https://clinicalstudies.info.nih.gov/protocoldetails.aspx?id=000344-DK&&query=, identifier NCT04969926.